Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AVI BioPharma reports encouraging clinical data from phase II Avicine study

Dec. 15, 1998

MAb-tyrosine kinase inhibitor immunoconjugate induces disease remission in ALL patients

Dec. 14, 1998

Novel GM-CSF-containing fusion toxin shows excellent antileukemia activity in mouse model

Dec. 14, 1998

Lorus Therapeutics announces final phase I/II pancreatic cancer trial data

Dec. 11, 1998

Preliminary indications support safety and efficacy of 90Y-labeled lintuzumab in AML

Dec. 10, 1998

MGI Pharma expands prostate cancer study with MGI-114

Dec. 10, 1998

Techniclone initiates phase II trial for treatment of malignant glioma

Dec. 9, 1998

CMA-676 shows efficacy and excellent tolerability in patients with AML

Dec. 9, 1998

Excellent results obtained in AML patients receiving Maxamine plus IL-2

Dec. 9, 1998

U.S. patent covers Coulter's antibody therapy for B-cell lymphoma

Dec. 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...